Our Story
Discover Our Journey So Far
In 1999. Dr. Behnam Ghasemzadeh came across an article that described the use of brain targets for treatment of memory diseases and Alzheimer’s. Despite struggles finding funding and patent approval, preliminary experiments showed promise in treatment of schizophrenia. Ten years later Avimed Pharma was founded in 200g.
Our Vision
Our Vision
To develop a first in class medication for treatment of cognitive dysfunction that exists in Schizophrenia, and a range of other mental disorders, without serious side effects. These dysfunctions are shared amongst a range of other CNS disorders such as autism. depression. and Alzheimer’s. Through these treatments we seek to improve the quality of life of individuals and their families who suffer from these disorders
Our Team
To develop a first in class medication for treatment of cognitive dysfunction that exists in Schizophrenia, and a range of other mental disorders, without serious side effects. These dysfunctions are shared amongst a range of other CNS disorders such as autism. depression. and Alzheimer’s. Through these treatments we seek to improve the quality of life of individuals and their families who suffer from these disorders
DR. DANIEL SEM Ph.D. J.D. M.B.A.
CEO & VP OF DRUG DEVELOPMENT
Associate Professor of Pharmaceutical Sciences and Director of Technology Transfer at Concordia University Wisconsin
Dean of the Batterman School of Business at Concordia University
Wisconsin
Over 25 years experience in inhibitor and drug design
Relevant biotech experience: Cofounded Triad until it was sold its drug program to Novartis
7 issued + 20 pending patents
50 papers and 10 issued patents on drug discovery and development techniques
Developed AviMed’s repurposing platform technology
Scientific Co-Founder of AviMed Pharmaceuticals
DR. DANIEL SEM Ph.D. J.D. M.B.A.
CEO & VP OF DRUG DEVELOPMENT
Associate Professor of Pharmaceutical Sciences and Director of Technology Transfer at Concordia University Wisconsin
Dean of the Batterman School of Business at Concordia University
Wisconsin
Over 25 years experience in inhibitor and drug design
Relevant biotech experience: Cofounded Triad until it was sold its drug program to Novartis
7 issued + 20 pending patents
50 papers and 10 issued patents on drug discovery and development techniques
Developed AviMed’s repurposing platform technology
Scientific Co-Founder of AviMed Pharmaceuticals